Memphasys believes it has found a quicker, cheaper way to get its Felix sperm separation system cleared by US regulators. It could open a door to an IVF market worth about US$5.9 billion.

Paradigm Biopharmaceuticals has suffered a setback after an independent monitoring board found that its Phase 3 knee osteoarthritis trial failed to meet the efficacy threshold required to continue.

Melbourne kidney disease drug developer Dimerix has drawn $17 million from a $34 million loan facility as its lead candidate goes through a pivotal Phase 3 trial.

The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA phase 2b/3 trial remain on track for November.

Prescient Therapeutics has raised $6 million from shareholders and investors. The money will fund its lead cancer drug through a December dosing review and into the next stage of clinical development.

Seven Australian startups will share $15.6 million to speed up the development of new treatments, diagnostic tools and technologies for dementia and cognitive decline.

Perth company Patrys has started in-human testing of its intravenous version of the antipsychotic quetiapine. The first healthy volunteers have now been dosed in a Phase 1a trial of the drug, known as RLS-2202.

BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally later.

The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 billion upfront on a cash-free, debt-free basis for a German company that supplies the raw material the entire targeted radionuclide therapy industry depends on.

Genetic Signatures and Microba Life Sciences have agreed on the principal commercial terms of a merger that would combine two ASX-listed Australian diagnostics businesses into a single group.

Managing Director and Chief Executive James Bonnar said, "This capital raise marks a pivotal moment for Nyrada. The strong support from both new and existing investors is a powerful validation of our science, our team, our novel drug Xolatryp, and our potential to address serious unmet clinical needs."

Anthropic has expanded its AI for Science commitment in Australia with an additional $10 million in Claude API credit grants, bringing its total investment in Australian research to $13 million since the program launched in April.

A Melbourne biotechnology company betting on immune cell cargo as a treatment for Alzheimer's disease has enlisted one of Australia's best-known stem cell laboratories to find out whether the idea holds up in human brain tissue.

Paradigm Biopharmaceuticals has appointed a new Chief Medical Officer as its osteoarthritis program moves from recruitment into a potential regulatory submission.

Cambium Bio has secured a $10.85 million funding package for the pivotal Phase 3 trial of its dry eye treatment Elate Ocular.

Hydrix has landed a multi-year contract with the National Heart Centre Singapore, giving the ASX-listed technology group a foothold in one of Asia's most prominent cardiac hospitals and a reference customer it hopes will open doors across the region.

Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest-to-treat forms of cancer.